

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Image
DAC
(I) ~~4~~
PATENT

ATTORNEY DOCKET NUMBER: 00786/351004

Certificate of Mailing: Date of Deposit: March 30, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Colleen Coyne

Printed name of person mailing correspondence

Colleen Coyne

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gary Ruvkun et al.	Art Unit:	1636
Serial No.:	09/205,658	Examiner:	S. Kaushal
Filed:	December 3, 1998	Customer No.:	21559
Title:	THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED GLUCOSE TOLERANCE CONDITIONS		

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AFTER ALLOWANCE UNDER 37 C.F.R. § 1.312


Applicants hereby resubmit a copy of Information Disclosure Statement and Form PTO-1449 that was previously submitted in connection with the above-referenced application on March 5, 2003. Copies of the references cited are submitted herewith. In addition, a copy of the date-stamped postcard is also enclosed. Applicants did not receive an initialed copy of the Form PTO-1449 and respectfully request that it be provided.

If there are any additional charges or any credits, please apply them to Deposit

Account No. 03-2095.

Respectfully submitted,


Date: 30 March 2004



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

F:\00786\351xxx\00786.351004 Amendment After Allowance.doc



PATENT
ATTORNEY DOCKET NO. 00786/351004

Certificate of Mailing: Date of Deposit: March 5, 2003

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Tracey Simmons
Printed name of person mailing correspondence

Tracey Simmons
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gary Ruvkun et al.	Art Unit:	1633
Serial No.:	09/205,658	Examiner:	S. Kaushal
Filed:	December 3, 1998	Customer No.:	21559
Title:	THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED GLUCOSE TOLERANCE CONDITIONS		

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. I, the undersigned, hereby

certify that each item of information contained in this statement was first cited in a communication from a foreign patent office in a counterpart foreign application, dated December 6, 2002, which is not more than three months prior to the filing of this statement.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 5 March 2003



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045




21559

PATENT TRADEMARK OFFICE

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.		00786/351004	
				Serial No.		09/205,658	
				Applicant		Gary Ruvkun et al.	
				Filing Date		December 3, 1998	
				Group		1633	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		(37 C.F.R. § 1.98(b))		IDS Filed		March 5, 2003	
				Customer No.		21559	
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
	WO 98/33907	08/06/98	PCT				
	WO 98/51351	11/19/98	PCT				
	WO 01/07457 A1	02/01/01	PCT				
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
	Maehama et al., "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate," <i>J. Biol. Chem.</i> 273:13375-13378 (1998).						
	Mihaylova et al., "The PTEN tumor suppressor homolog in <i>Caenorhabditis elegans</i> regulates longevity and dauer formation in an insulin receptor-like signaling pathway," <i>Proc. Natl. Acad. Sci. USA</i> 96:7427-32 (1999).						
	Rouault et al., "Regulation of dauer larva development in <i>Caenorhabditis elegans</i> by <i>daf-18</i> , a homologue of the tumour suppressor PTEN," <i>Current Biol.</i> 9:329-332 (1999).						
	Scheet et al., "Direct Submission: T07A9.6 protein (DAF-18 protein)," (Accession No. 044405) European Bioinformatics Institute, European Molecular Biology Laboratory (1998).						
	Stephens et al., "Protein kinase B kinases that mediate phosphatidylinositol 3, 4, 5 - trisphosphate-dependent activation of protein kinase B," <i>Science</i> 279:710-714 (1998).						
	The <i>C. elegans</i> Sequencing Consortium, "Genome sequence of the nematode <i>C. elegans</i> : A platform for investigating biology," <i>Science</i> , 282:2012-2018 (1998).						
	Waterston, "Direct Submission: <i>Caenorhabditis elegans</i> cosmid T07A9," (Accession No. AF036706) European Bioinformatics Institute, European Molecular Biology Laboratory (1997).						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							



****PROSECUTION****

PATENT
ATTORNEY DOCKET NUMBER: 00786/351004

The U.S. PTO date stamp sets forth the date of receipt of:

Applicant/Patentee: Gary Ruvkun et al.

Serial/Patent Number: 09/205,658

Filed/Issued: December 3, 1998

Title: THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED GLUCOSE TOLERANCE

CONDITIONS

<input type="checkbox"/> Transmittal Letter	Pages: _____	<input type="checkbox"/> Declaration & POA	Pages: _____
<input type="checkbox"/> Notice of Missing Parts	Pages: _____	<input type="checkbox"/> Assignment & Cover Sheet	Pages: _____
<input type="checkbox"/> Reply to Missing Parts	Pages: _____	<input type="checkbox"/> Change of Address	Pages: _____
<input type="checkbox"/> Reply to Examiner's Action	Pages: _____	<input type="checkbox"/> Small Entity Statement	Pages: _____
<input type="checkbox"/> Extension of Time	Pages: _____	<input type="checkbox"/> Preliminary Amendment	Pages: _____
<input type="checkbox"/> Notice of Appeal	Pages: _____	<input checked="" type="checkbox"/> IDS	Pages: <u>2</u>
<input type="checkbox"/> Appeal Brief	Pages: _____	<input checked="" type="checkbox"/> Cited References	Number: <u>10</u>
<input type="checkbox"/> Drawings Formal/Informal	Pages: _____	<input checked="" type="checkbox"/> Other <u>PTO-1449</u>	Pages: <u>1</u>
<input type="checkbox"/> M-Fee Payment	Pages: _____	<input type="checkbox"/> Other _____	Pages: _____
<input type="checkbox"/> Issue Fee Payment	Pages: _____		
<input checked="" type="checkbox"/> Check	\$: _____		

☒ Other International Search Report

Pages: 9

Atty/Secy: KLE/MHE/lms Client/Matter Name: Ruvkun MGH-1170.3

Date: 3-5-03

